Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Product candidates
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
01 August 2017
GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
23 June 2017
Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics
22 June 2017
GenSight Biologics launches a capital increase of approximately €20 million
14 June 2017
GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
08 May 2017
GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
27 April 2017
GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit
20 April 2017
GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology
28 March 2017
GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS
21 February 2017
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
31 January 2017
GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa
View previous 9 articles
1
…
10
11
12
13
14
15
16
View next 9 articles
Go back to the page of the page